Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.B1 (
angiotensin-converting enzyme 2
)
1,025
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Alzheimer's disease is a chronic neurodegenerative disorder and represents the main cause of dementia. Currently, the world is suffering from the pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that uses
angiotensin-converting enzyme 2
(
ACE2
) as a receptor to enter the host cells. In COVID-19, neurological manifestations have been reported to occur. The present study demonstrates that the protein expression level of
ACE2
is upregulated in the brain of Alzheimer's disease patients. The increased
ACE2
expression is not age-dependent, suggesting the direct relationship between Alzheimer's disease and the
ACE2
expression. Oxidative stress has been implicated in the pathogenesis of Alzheimer's disease, and Alzheimer's disease brains examined in this study also exhibited higher carbonylated proteins as well as increased thiol oxidation state of
peroxiredoxin 6
(Prx6). The positive correlation was found between the increased
ACE2
protein expression and oxidative stress in Alzheimer's disease brain. Thus, the present study reveals the relationships between Alzheimer's disease and
ACE2
, the receptor for SARS-CoV-2. These results warrant monitoring Alzheimer's disease patients with COVID-19 carefully for the possible higher viral load in the brain and long-term adverse neurological consequences.
...
PMID:Angiotensin-converting enzyme 2 (ACE2) is upregulated in Alzheimer's disease brain. 3305 46